Display options
Cite
Li J, Verhaar AP, Pan Q, et al. Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clin Exp Gastroenterol. 2017;10:203-209doi: 10.2147/CEG.S135526.
Li, J., Verhaar, A. P., Pan, Q., de Knegt, R. J., & Peppelenbosch, M. P. (2017). Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clinical and experimental gastroenterology, 10203-209. https://doi.org/10.2147/CEG.S135526
Li, Juan, et al. "Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B." Clinical and experimental gastroenterology vol. 10 (2017): 203-209. doi: https://doi.org/10.2147/CEG.S135526
Li J, Verhaar AP, Pan Q, de Knegt RJ, Peppelenbosch MP. Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clin Exp Gastroenterol. 2017 Aug 11;10:203-209. doi: 10.2147/CEG.S135526. eCollection 2017. PMID: 28860836; PMCID: PMC5560566.
Copy Download .nbib Format: NLM
Share it on

Clin Exp Gastroenterol. 2017 Aug 11;10:203-209. doi: 10.2147/CEG.S135526. eCollection 2017.

Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B.

Clinical and experimental gastroenterology

Juan Li, Auke P Verhaar, Qiuwei Pan, Robert Jacobus de Knegt, Maikel P Peppelenbosch

Affiliations

  1. Erasmus MC Cancer Institute, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands.

PMID: 28860836 PMCID: PMC5560566 DOI: 10.2147/CEG.S135526

Abstract

BACKGROUND AND AIM: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a potential clinically useful biomarker in liver disease as it is released from hepatocytes during apoptosis. In this study, we investigated serum CK18-Asp396 levels in chronic hepatitis B (CHB).

PATIENTS AND METHODS: Overall, 163 patients with CHB were included. Serum CK18-Asp396 levels were determined by enzyme-linked immunosorbent assay (ELISA), and results were related to steatosis grade, histological activity index, inflammation score, and METAVIR fibrosis grade as well as to viral load, serum levels of liver enzymes, and albumin. Receiver operating characteristic analysis was used to evaluate the diagnostic performance of serum CK18-Asp396 levels for assessing disease activity.

RESULTS: A higher level of serum CK 18 concentrations was found in patients with significant inflammation vs no significant inflammation (378.5 [interquartile range {IQR}: 173.2-629.6] vs 137.3 [87.5-197.7],

CONCLUSION: CHB appears to be accompanied by continuous high levels of hepatocyte apoptosis as judged from serum CK 18, suggesting that elimination of the infected compartment constitutes a defensive strategy against disease. Accordingly, CK 18 works as an independent predictor of significant inflammation with a high specificity.

Keywords: CHB; CK 18; apoptosis; inflammation; steatosis

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Am J Gastroenterol. 1999 Sep;94(9):2467-74 - PubMed
  2. Afr Health Sci. 2015 Sep;15(3):714-8 - PubMed
  3. Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4123-9 - PubMed
  4. Hepat Mon. 2013 Jun 26;13(6):e10106 - PubMed
  5. N Engl J Med. 1997 Dec 11;337(24):1733-45 - PubMed
  6. Rev Med Virol. 2011 Sep;21(5):315-29 - PubMed
  7. J Hepatol. 1995 Jun;22(6):696-9 - PubMed
  8. Rev Med Virol. 2014 Mar;24(2):125-38 - PubMed
  9. Clin Exp Gastroenterol. 2014 Jul 05;7:221-39 - PubMed
  10. Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1103-9 - PubMed
  11. Liver Int. 2015 Feb;35(2):438-47 - PubMed
  12. Hepatology. 2016 Jan;63(1):261-83 - PubMed
  13. J Hepatol. 2003 Sep;39(3):414-20 - PubMed
  14. Med Sci Monit. 2009 Apr;15(4):CR189-93 - PubMed
  15. Clin Exp Gastroenterol. 2014 Aug 11;7:261-72 - PubMed
  16. Clin Chim Acta. 2010 Dec 14;411(23-24):2029-32 - PubMed
  17. Am J Physiol. 1996 Sep;271(3 Pt 1):C982-93 - PubMed
  18. Histopathology. 2002 May;40(5):403-39 - PubMed
  19. BMC Bioinformatics. 2011 Mar 17;12:77 - PubMed
  20. Hepat Mon. 2015 May 23;15(5):e25328 - PubMed
  21. Hepatology. 2000 Sep;32(3):477-81 - PubMed
  22. J Clin Virol. 2013 Dec;58(4):641-6 - PubMed
  23. Hepatology. 1996 Aug;24(2):289-93 - PubMed
  24. J Hepatol. 2014 Jan;60(1):167-74 - PubMed
  25. Cancer Lett. 2004 Oct 8;214(1):1-9 - PubMed
  26. J Viral Hepat. 2003 May;10(3):159-67 - PubMed
  27. J Viral Hepat. 2012 Apr;19(4):278-82 - PubMed
  28. Am J Clin Nutr. 2004 Dec;80(6):1618-25 - PubMed
  29. Hepatology. 2017 Jun;65(6):1840-1850 - PubMed
  30. Clin Chim Acta. 2004 Nov;349(1-2):203-11 - PubMed
  31. Am J Gastroenterol. 2006 Nov;101(11):2537-45 - PubMed
  32. Liver Int. 2012 Apr;32(4):622-8 - PubMed
  33. Dig Liver Dis. 2016 Jan;48(1):55-61 - PubMed
  34. J Hepatol. 2002 Sep;37(3):400-10 - PubMed

Publication Types